Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II durvalumab plus prednisone in pretreated advanced or metastatic NSCLC patients receiving concomitant steroids
2018-003645-41Phase 2Completed
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and prednisone in non-small cell lung cancer (NSCLC), sponsored by Fondazione Ricerca Traslazionale. Primary endpoint: Objective response rate. Started Jun 2021; status: completed.
02
Drugs
durvalumabprednisone
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-003645-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003645-41.